Literature DB >> 33681986

Observational study of adult respiratory infections in primary care clinics in Myanmar: understanding the burden of melioidosis, tuberculosis and other infections not covered by empirical treatment regimes.

Clare E Warrell1,2, Aung Pyae Phyo1, Mo Mo Win3, Alistair R D McLean1,4, Wanitda Watthanaworawit5, Myo Maung Maung Swe1, Kyaw Soe1, Htet Naing Lin1,2, Yee Yee Aung3, Chitmin Ko Ko2, Cho Zin Waing2, Kaung San Linn2, Yadanar Phoo Wai Aung2, Ne Myo Aung6,7, Ni Ni Tun1,2, David A B Dance4,8,9, Frank M Smithuis1,2, Elizabeth A Ashley1,8,9.   

Abstract

BACKGROUND: Lower respiratory infections constitute a major disease burden worldwide. Treatment is usually empiric and targeted towards typical bacterial pathogens. Understanding the prevalence of pathogens not covered by empirical treatment is important to improve diagnostic and treatment algorithms.
METHODS: A prospective observational study in peri-urban communities of Yangon, Myanmar was conducted between July 2018 and April 2019. Sputum specimens of 299 adults presenting with fever and productive cough were tested for Mycobacterium tuberculosis (microscopy and GeneXpert MTB/RIF [Mycobacterium tuberculosis/resistance to rifampicin]) and Burkholderia pseudomallei (Active Melioidosis Detect Lateral Flow Assay and culture). Nasopharyngeal swabs underwent respiratory virus (influenza A, B, respiratory syncytial virus) polymerase chain reaction testing.
RESULTS: Among 299 patients, 32% (95% confidence interval [CI] 26 to 37) were diagnosed with tuberculosis (TB), including 9 rifampicin-resistant cases. TB patients presented with a longer duration of fever (median 14 d) and productive cough (median 30 d) than non-TB patients (median fever duration 6 d, cough 7 d). One case of melioidosis pneumonia was detected by rapid test and confirmed by culture. Respiratory viruses were detected in 16% (95% CI 12 to 21) of patients.
CONCLUSIONS: TB was very common in this population, suggesting that microscopy and GeneXpert MTB/RIF on all sputum samples should be routinely included in diagnostic algorithms for fever and cough. Melioidosis was uncommon in this population.
© The Author(s) 2021. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Entities:  

Keywords:  zzm321990 Burkholderia pseudomalleizzm321990 ; Myanmar; influenza; melioidosis; respiratory infection; tuberculosis

Mesh:

Year:  2021        PMID: 33681986      PMCID: PMC8326957          DOI: 10.1093/trstmh/trab024

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  31 in total

1.  Community-wide Screening for Tuberculosis in a High-Prevalence Setting.

Authors:  Guy B Marks; Nhung V Nguyen; Phuong T B Nguyen; Thu-Anh Nguyen; Hoa B Nguyen; Khoa H Tran; Son V Nguyen; Khanh B Luu; Duc T T Tran; Qui T N Vo; Oanh T T Le; Yen H Nguyen; Vu Q Do; Paul H Mason; Van-Anh T Nguyen; Jennifer Ho; Vitali Sintchenko; Linh N Nguyen; Warwick J Britton; Greg J Fox
Journal:  N Engl J Med       Date:  2019-10-03       Impact factor: 91.245

2.  The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study.

Authors:  Bart J Currie; Linda Ward; Allen C Cheng
Journal:  PLoS Negl Trop Dis       Date:  2010-11-30

3.  Sputum smear-positive, Xpert® MTB/RIF-negative results: magnitude and treatment outcomes of patients in Myanmar.

Authors:  M H Phyu; K W Y Kyaw; Z Myint; A Thida; S Satyanarayana; S T Aung
Journal:  Public Health Action       Date:  2018-12-21

4.  Evaluation of a latex agglutination assay for the identification of Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Brea D Duval; Mindy G Elrod; Jay E Gee; Narisara Chantratita; Sarunporn Tandhavanant; Direk Limmathurotsakul; Alex R Hoffmaster
Journal:  Am J Trop Med Hyg       Date:  2014-04-07       Impact factor: 2.345

5.  Urban-rural differences in the prevalence of non-communicable diseases risk factors among 25-74 years old citizens in Yangon Region, Myanmar: a cross sectional study.

Authors:  Aung Soe Htet; Marius B Bjertness; Lhamo Y Sherpa; Marte Karoline Kjøllesdal; Win Myint Oo; Haakon E Meyer; Hein Stigum; Espen Bjertness
Journal:  BMC Public Health       Date:  2016-12-05       Impact factor: 3.295

6.  A Study of Burkholderia pseudomallei in the Environment of Farms in Thanlyin and Hmawbi Townships, Myanmar.

Authors:  Mo Mo Win; Thaung Hla; Khin Phyu Phyu; Wah Wah Aung; Kyi Kyi Nyein Win; Su Nyein Aye; Thin Thin Wah; Khin Mar Aye; Tin Tin Htwe; May Than Htay; Kyaw Kyaw San; David Allan Brett Dance
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

7.  Urban-rural differences in the prevalence of diabetes mellitus among 25-74 year-old adults of the Yangon Region, Myanmar: two cross-sectional studies.

Authors:  Wai Phyo Aung; Aung Soe Htet; Espen Bjertness; Hein Stigum; Virasakdi Chongsuvivatwong; Marte Karoline Råberg Kjøllesdal
Journal:  BMJ Open       Date:  2018-03-30       Impact factor: 2.692

8.  Evaluation of a Rapid Diagnostic Test for Detection of Burkholderia pseudomallei in the Lao People's Democratic Republic.

Authors:  Kate L Woods; Latsaniphone Boutthasavong; Caoimhe NicFhogartaigh; Sue J Lee; Viengmon Davong; David P AuCoin; David A B Dance
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

Review 9.  Melioidosis in Myanmar.

Authors:  Mo Mo Win; Elizabeth A Ashley; Khwar Nyo Zin; Myint Thazin Aung; Myo Maung Maung Swe; Clare L Ling; François Nosten; Win May Thein; Ni Ni Zaw; May Yee Aung; Kyaw Myo Tun; David A B Dance; Frank M Smithuis
Journal:  Trop Med Infect Dis       Date:  2018-03-01

10.  Myanmar Burkholderia pseudomallei strains are genetically diverse and originate from Asia with phylogenetic evidence of reintroductions from neighbouring countries.

Authors:  Jessica R Webb; Mo Mo Win; Khwar Nyo Zin; Kyi Kyi Nyein Win; Thin Thin Wah; Elizabeth A Ashley; Frank Smithuis; Myo Maung Maung Swe; Mark Mayo; Bart J Currie; David A B Dance
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.